Emergent Biosolutions, Inc. (NYSE:EBS) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Friday.

Separately, Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Emergent Biosolutions has an average rating of “Hold” and a consensus target price of $40.33.

Emergent Biosolutions (NYSE EBS) traded down 0.11% during midday trading on Friday, reaching $35.18. 1,346,387 shares of the company’s stock traded hands. Emergent Biosolutions has a 52-week low of $24.47 and a 52-week high of $36.81. The firm has a market cap of $1.44 billion, a PE ratio of 27.97 and a beta of 1.22. The firm’s 50-day moving average is $34.24 and its 200 day moving average is $31.22.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by $0.13. The firm had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.05) EPS. Equities research analysts expect that Emergent Biosolutions will post $1.58 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/06/emergent-biosolutions-inc-ebs-downgraded-to-hold-at-bidaskclub.html.

In other news, Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $35.50, for a total value of $887,500.00. Following the transaction, the chairman now owns 1,655,216 shares in the company, valued at $58,760,168. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 16.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. Federated Investors Inc. PA boosted its position in Emergent Biosolutions by 3.4% in the second quarter. Federated Investors Inc. PA now owns 245,002 shares of the biopharmaceutical company’s stock valued at $8,308,000 after buying an additional 8,098 shares during the last quarter. Legal & General Group Plc boosted its position in Emergent Biosolutions by 10.1% in the second quarter. Legal & General Group Plc now owns 67,333 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 6,193 shares during the last quarter. Alps Advisors Inc. boosted its position in Emergent Biosolutions by 5.6% in the second quarter. Alps Advisors Inc. now owns 36,967 shares of the biopharmaceutical company’s stock valued at $1,254,000 after buying an additional 1,964 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Emergent Biosolutions during the second quarter valued at $882,000. Finally, New Amsterdam Partners LLC NY bought a new position in Emergent Biosolutions during the second quarter valued at $3,331,000. 85.41% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.